Those who do not respond to at least two therapies, are regarded as having ‘treatment-resistant depression.’ Currently there are no approved treatments for patients with depression who are at an imminent risk for suicide. Esketamine is currently in development as a spray through the nose (intranasal) for the treatment of treatment-resistant depression in adults. Compared to treatment options that require injections, esketamine is less invasive and is considered easier to use as it is a nasal spray. If licensed, esketamine may be a safe and effective treatment option for this hard to treat population.
Evzio is being developed as an injectable device that contains naloxone, a drug used to reverse the effects of opioid drug overdose. It is designed to be easily administered by non-health professionals in a non-clinical setting. If licensed it has the potential to improve emergency responses to opioid overdoses as it can be used in the home environment, enabling caregivers to respond quickly and confidently due to the voice and visual guidance provided with the device.